Zepbound is Eli Lilly's brand of tirzepatide injection, FDA-approved for chronic weight management in adults and for moderate to severe obstructive sleep apnea in adults with obesity.
How Zepbound works in the body
Section 12 of the Zepbound label explains the mechanism. Tirzepatide binds and activates the GIP and GLP-1 receptors, the same targets as the body's own GIP and GLP-1. GLP-1 regulates appetite and calorie intake, and animal studies suggest GIP adds to the effect on food intake. Both receptors sit in brain areas that control appetite [1].
The molecule carries a fatty acid chain that binds to albumin in the blood, which stretches its half-life to about 5 to 6 days. That is why Zepbound is a once-weekly shot. Steady levels build after 4 weeks [1]. The label also notes that the weight lost is more fat than lean mass [1].
What the label's trials found
| Trial | Who | Result vs placebo | Length |
|---|---|---|---|
| Study 1 | Adults with obesity or overweight, no diabetes | Weight -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% | 72 weeks |
| Study 1 | Same | Waist -14.0 to -18.5 cm vs -4.0 cm; systolic blood pressure -6.6 to -7.7 vs -1.0 mmHg | 72 weeks |
| Study 2 | Adults with type 2 diabetes | Weight -12.8% (10 mg), -14.7% (15 mg) vs -3.2% | 72 weeks |
| Study 4 (SURMOUNT-4) | Lost 20.9% in a 36-week lead-in, then kept going or stopped | Continued: further -5.5%; switched to placebo: +14.0% | 88 weeks total |
| Studies 5 and 6 | Adults with obesity and moderate to severe sleep apnea | Breathing events fell 25.3 and 29.3 per hour vs 5.3 and 5.5 | 52 weeks |
Study 1 is the SURMOUNT-1 trial. In it, 85% to 91% of people on Zepbound lost at least 5% of their weight vs 35% on placebo, and 57% on 15 mg lost at least 20% [6]. These are trial averages and shares, not a forecast for any one person. How Study 2 bears on diabetes treatment is covered on Zepbound interactions.
When weight loss starts on Zepbound
Every Zepbound patient starts on 2.5 mg once weekly for 4 weeks. The label says this dose is for starting treatment and is not intended for maintenance [4]. The trials measured weight loss on 5, 10 and 15 mg, not on 2.5 mg [1]. After 4 weeks the dose goes to 5 mg, with optional 2.5 mg increases after at least 4 weeks on each dose [4]. The label reports results at week 72, not week by week. The full schedule is on Zepbound dosage.
Is Zepbound approved and safe for weight loss?
Yes, it is FDA-approved for weight. FDA approved it on November 8, 2023 for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition [2]. It is meant to be used with a reduced-calorie diet and more physical activity, and should not be combined with other tirzepatide products or GLP-1 drugs [4].
Safety has limits. Zepbound has a boxed warning for thyroid C-cell tumors seen in rats and must not be used with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. It should be stopped in pregnancy, and its safety in children has not been established [1]. In the pooled weight trials, 4.8% to 6.7% stopped for side effects vs 3.4% on placebo [1]. See Zepbound side effects.
Does it work for everyone?
No. In SURMOUNT-1, 9% to 15% of people on Zepbound did not reach 5% weight loss [6]. The label sets no target for how much you should lose. If you are gaining weight, or not losing on a maintenance dose, tell your prescriber; the label allows further dose steps up to 15 mg [4]. Our sources contain no data specific to weight gain on Zepbound.
Getting the most out of it, per the label
- Reach a maintenance dose. The label's weight maintenance doses are 5, 10 and 15 mg [4].
- Pair it with a reduced-calorie diet and more activity, as approved [4]. See GLP-1 diet plan.
- Keep the weekly rhythm. A missed dose can be taken within 4 days; after that, skip it [4].
- Stay on it if it is working for you. In Study 4, stopping led to an average regain of 14.0% [5].
Zepbound vs compounded tirzepatide
Every result on this page is for Zepbound. Compounded tirzepatide was not tested in these trials. It is not FDA-approved, and FDA does not review it for safety, effectiveness or quality [7]. FDA has told telehealth companies not to claim compounded drugs are the same as approved drugs or clinically proven to give the same results [8]. Read compounded tirzepatide and the molecule-level evidence on tirzepatide results.
Pens, vials and the price of staying on it
Zepbound comes as a single-dose pen, a single-dose vial, a 4-dose KwikPen and a multi-dose vial [4]. On LillyDirect, checked October 17, 2026, the vial and KwikPen cost $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg if each refill comes within 45 days. Miss that window and 7.5 mg is $499 and 10 to 15 mg is $699. LillyDirect counts a month as 28 days, and KwikPen users buy pen needles separately [9]. Medicare's GLP-1 Bridge covers only the Zepbound KwikPen, with a $50 monthly copay for those who qualify [10] [11]. Details: Zepbound cost and Zepbound insurance.
Questions people ask
How does Zepbound work?
Zepbound (tirzepatide) activates GIP and GLP-1 receptors, including in brain areas that control appetite, and slows stomach emptying, which lowers food intake [1].
How long does it take for Zepbound to work?
How much weight can you lose on Zepbound?
In Study 1 on the label, average weight loss at 72 weeks was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, vs 3.1% on placebo [1]. Individual results varied.
Is Zepbound FDA-approved for weight loss?
Yes. FDA approved Zepbound for chronic weight management on November 8, 2023, for adults with a BMI of 30 or more, or 27 or more with a weight-related condition [2].
How long has Zepbound been on the market?
Can you lose weight on Zepbound 2.5 mg?
Does Zepbound work for everyone?
No. In SURMOUNT-1, 85% to 91% of people on Zepbound lost at least 5% of their weight, so 9% to 15% did not [6].
Is Zepbound safe for weight loss?
It is FDA-approved for weight, with warnings. It has a boxed warning for thyroid C-cell tumors in rats, and 4.8% to 6.7% of trial participants stopped for side effects vs 3.4% on placebo [1].
Does compounded tirzepatide work as well as Zepbound?
There is no trial showing it. Compounded tirzepatide is not FDA-approved and FDA does not review it for safety, effectiveness or quality [7].
Sources
11 cited
- Zepbound (tirzepatide) prescribing information, revised 04/2026. U.S. Food and Drug Administration, Apr 2026.
- FDA approves new medication for chronic weight management. U.S. Food and Drug Administration, Nov 8, 2023.
- FDA approves first medication for obstructive sleep apnea. U.S. Food and Drug Administration, Dec 20, 2024.
- Zepbound (tirzepatide) label, revised 8/2026. DailyMed, U.S. National Library of Medicine, Aug 28, 2026.
- SURMOUNT-4 trial abstract (Aronne et al., JAMA 2024). JAMA, via PubMed, Jan 1, 2024.
- SURMOUNT-1 trial abstract (Jastreboff et al., NEJM 2022). New England Journal of Medicine, via PubMed, Jun 4, 2022.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
- Telehealth companies: what to know when promoting compounded drugs. U.S. Food and Drug Administration, Jun 15, 2026.
- Zepbound on LillyDirect: self-pay prices. Eli Lilly and Company, Oct 17, 2026.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, Oct 17, 2026.
- Weight loss drugs coverage. Medicare.gov (CMS), Oct 17, 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.